ANTX insider transactions
AN2 Therapeutics Inc. (ANTX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for ANTX
- Principal Accounting Officer Williams Sarah Joanne sold $1,174 worth of shares (265 units at $4.43), decreasing direct ownership by 0.40% to 66,583 units (SEC Form 4) to satisfy withholding obligation4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Aziz Kabeer4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Marks Gilbert Lynn4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Martin Patricia A.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Day Lucy4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Chanda Sanjay4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Marks Gilbert Lynn4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Aziz Kabeer4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Martin Patricia A.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Fitzpatrick Margaret M4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Wong Stephanie4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Zakrzewski Joseph S4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Eizen Joshua M4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Spigelman Melvin K4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Readnour Robin Shane4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Easom Eric4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Principal Accounting Officer Williams Sarah Joanne sold $347 worth of shares (327 units at $1.06), decreasing direct ownership by 0.49% to 66,848 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Officer Eizen Joshua M was granted 50,000 shares, increasing direct ownership by 32% to 207,499 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Chief Financial Officer Day Lucy was granted 38,000 shares, increasing direct ownership by 47% to 118,363 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Principal Accounting Officer Williams Sarah Joanne was granted 48,375 shares, increasing direct ownership by 257% to 67,175 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Chief Executive Officer Easom Eric was granted 112,250 shares, increasing direct ownership by 44% to 368,630 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Chief Development Officer Chanda Sanjay was granted 38,000 shares, increasing direct ownership by 47% to 118,823 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Marks Gilbert Lynn4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Readnour Robin Shane4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Wong Stephanie4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Martin Patricia A.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Spigelman Melvin K4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Aziz Kabeer4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Fitzpatrick Margaret M4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Zakrzewski Joseph S4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- New insider Williams Sarah Joanne claimed ownership of 18,800 shares (SEC Form 3)3 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Aziz Kabeer was granted 11,560 shares, increasing direct ownership by 28% to 52,479 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Martin Patricia A. was granted 3,650 shares, increasing direct ownership by 28% to 16,905 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Marks Gilbert Lynn was granted 11,560 shares, increasing direct ownership by 18% to 75,309 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Chief Financial Officer Day Lucy sold $8,883 worth of shares (8,807 units at $1.01), decreasing direct ownership by 10% to 75,363 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Chief Strategy Officer Prior Stephen David sold $6,507 worth of shares (6,462 units at $1.01), decreasing direct ownership by 10% to 59,086 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Chief Development Officer Chanda Sanjay sold $9,332 worth of shares (9,251 units at $1.01), decreasing direct ownership by 11% to 75,823 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Officer Eizen Joshua M sold $24,962 worth of shares (24,854 units at $1.00), decreasing direct ownership by 14% to 152,499 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Officer Eizen Joshua M sold $3,214 worth of shares (2,819 units at $1.14), decreasing direct ownership by 2% to 177,353 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Chief Strategy Officer Prior Stephen David sold $872 worth of shares (765 units at $1.14), decreasing direct ownership by 1% to 65,548 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Martin Patricia A. was granted 3,274 shares, increasing direct ownership by 33% to 13,255 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Aziz Kabeer was granted 10,367 shares, increasing direct ownership by 34% to 40,919 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Marks Gilbert Lynn was granted 10,367 shares, increasing direct ownership by 19% to 63,749 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Aziz Kabeer was granted 11,875 shares, increasing direct ownership by 64% to 30,552 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Marks Gilbert Lynn was granted 11,875 shares, increasing direct ownership by 29% to 53,382 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Martin Patricia A. was granted 3,750 shares, increasing direct ownership by 60% to 9,981 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Large owner Leonard Braden Michael sold $218,000 worth of shares (200,000 units at $1.09) (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Chief Executive Officer Easom Eric bought $10,665 worth of shares (10,000 units at $1.07), increasing direct ownership by 4% to 256,380 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Large owner Leonard Braden Michael sold $2,872,477 worth of shares (2,532,000 units at $1.13) (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Fitzpatrick Margaret M bought $10,133 worth of shares (8,610 units at $1.18) (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Readnour Robin Shane4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Martin Patricia A.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Fitzpatrick Margaret M4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Zakrzewski Joseph S4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Spigelman Melvin K4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Wong Stephanie4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Marks Gilbert Lynn4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SEC Form 4 filed by Director Aziz Kabeer4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Zakrzewski Joseph S was granted 10,523 shares, increasing direct ownership by 8% to 145,538 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- Director Aziz Kabeer was granted 9,705 shares, increasing direct ownership by 108% to 18,677 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)